View our range of modules specifically designed for healthcare professionals (HCPs), highlighting the pathophysiology and management of SCD.

These modules are accredited by the Continuing Professional Development (CPD) Certification Service and will each take approximately 45 minutes to complete.

 

Image with text saying 'Sickle cell disease (SCD) Therapeutic curriculum disease area module disease state and pathophysiology haematology academy'. Title 'Disease state and pathophysiology' accompanying the image.

Disease state and pathophysiology

A comprehensive overview of the disease state of SCD, including pathophysiology, complications and risks.

View

 

Image with text saying 'Sickle cell disease (SCD) Therapeutic curriculum disease area module disease state and pathophysiology haematology academy'. Title<br />
'SCD management and treatment landscape' accompanying the image.

SCD management and treatment landscape

A training module covering the therapeutic landscape for SCD and its complications.

View

 

 Image with text saying 'Sickle cell disease (SCD) Therapeutic curriculum disease area module disease state and pathophysiology haematology academy'. Title  'Crizanlizumab – clinical data' accompanying the image.

Crizanlizumab – clinical data

An overview of the SUSTAIN study detailing the use of crizanlizumab in the prevention of recurrent vaso-occlusive crises (VOCs).

Coming soon

 

Indication: Crizanlizumab is indicated for the prevention of recurrent VOCs in patients with SCD who are aged 16 years and over. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate.1

Crizanlizumab has a conditional marketing authorisation and further evidence is awaited.

Abbreviations: CPD, continuing professional development; HC, hydroxycarbamide; HCPs, healthcare professionals; HU, hydroxyurea; SCD, sickle cell disease; VOCs, vaso-occlusive crises.

Reference

  1. ADAKVEO® (crizanlizumab) Summary of Product Characteristics.

For more information, refer to the ADAKVEO® prescribing information available here:
https://www.health.novartis.co.uk/sites/health.novartis.co.uk/files/adakveo-pi.pdf

Legal Category: POM

Marketing Authorisation (MA) number, quantities and price: EU/1/20/1476/001 £1,038.00 per 10ml vial

Rate this content: 
No votes yet
UK | June 2021 | 115136
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]